Publications by authors named "Hartmut Kupper"

Claim this Profile
A
A first-in-human study of the novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants.
Ronilda D'Cunha, Hartmut Kupper, Dilek Arikan, Weihan Zhao, David Carter

Br J Clin Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich, Anna Zubrzycka-Sienkiewicz, Su Chen, Hartmut Kupper

Arthritis Rheumatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results.
Hermine I Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, Hartmut Kupper

Arthritis Care Res (Hoboken)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA.
Alla Skapenko, Josef S Smolen, Arthur Kavanaugh, Vipin Arora, Hartmut Kupper

Clin Exp Rheumatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial.
Burkhard Möller, Judith Everts-Graber, Stefan Florentinus, Yihan Li, Hartmut Kupper

Arthritis Care Res (Hoboken)· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial.
Gurjit S Kaeley, Daryl K MacCarter, Janak R Goyal, Shufang Liu, Kun Chen, Hartmut Kupper

Rheumatol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.
Edward C Keystone, Ferdinand C Breedveld, Hartmut Kupper, Yihan Li, Stefan Florentinus

RMD Open· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
Arthur Kavanaugh, Ronald F van Vollenhoven, Roy Fleischmann, Paul Emery, Iain Sainsbury, Hartmut Kupper

Ann Rheum Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
Sandra L Goss, Cheri E Klein, Ziyi Jin, Charles S Locke, Ramona C Rodila, Hartmut Kupper

Clin Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.
Gerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, Cem Gabay, Daryl K MacCarter, Hartmut Kupper

RMD Open· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.
Edward C Keystone, Ferdinand C Breedveld, Désirée van der Heijde, Ronald F van Vollenhoven, Paul Emery, Hartmut Kupper

RMD Open· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
Gurjit S Kaeley, Midori J Nishio, Janak R Goyal, Daryl K MacCarter, Alvin F Wells, Hartmut Kupper

Arthritis Rheumatol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
Paul Emery, Josef S Smolen, Arijit Ganguli, Sebastian Meerwein, Yanjun Bao, Hartmut Kupper

Rheumatology (Oxford)· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
Gurjit S Kaeley, Amy M Evangelisto, Midori J Nishio, Sandra L Goss, Shufang Liu, Hartmut Kupper

J Rheumatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
Daniel E Furst, Arthur Kavanaugh, Stefan Florentinus, Hartmut Kupper, Mahinda Karunaratne

Rheumatology (Oxford)· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
Daniel J Kingsbury, Brigitte Bader-Meunier, Gina Patel, Vipin Arora, Jasmina Kalabic, Hartmut Kupper

Clin Rheumatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
Désirée van der Heijde, Maxime Breban, Dale Halter, Gino DiVittorio, Johan Bratt, Hartmut Kupper

Rheumatology (Oxford)· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.
Gerd-Rűdiger Burmester, Alan J Kivitz, Hartmut Kupper, Udayasankar Arulmani, Stefan Florentinus

Ann Rheum Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
Filip Van den Bosch, Arthur Kavanaugh, Martina Kron, Hartmut Kupper, Philip J Mease

J Rheumatol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to H Zeidler's comments on the CONCERTO study.
Gerd R Burmester, Alan Kivitz, Hartmut Kupper, Udayasankar Arulmani, Stefan Florentinus

Ann Rheum Dis· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
Hisashi Yamanaka, Naoki Ishiguro, Tsutomu Takeuchi, Nobuyuki Miyasaka, Masaya Mukai, Hartmut Kupper

Rheumatology (Oxford)· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Josef S Smolen, Paul Emery, Roy Fleischmann, Ronald F van Vollenhoven, Karel Pavelka, Hartmut Kupper

Lancet· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Edward C Keystone, Ferdinand C Breedveld, Désirée van der Heijde, Robert Landewé, Stefan Florentinus, Hartmut Kupper

J Rheumatol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.
Gerd R Burmester, Marco Matucci-Cerinic, Xavier Mariette, Francisco Navarro-Blasco, Sonja Kary, Hartmut Kupper

Arthritis Res Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
Edward C Keystone, Désirée van der Heijde, Arthur Kavanaugh, Hartmut Kupper, Shufang Liu

J Rheumatol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis